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Feto-maternal microchimerism (FMM) involves bidirectional cross-placental trafficking
during pregnancy, leading to a micro-chimeric state that can persist for decades. In
this manner a pregnant woman will harbor cells from her mother, as well as, cells
from her child. Historically, eclampsia, a severe disorder of pregnancy provided the
basis for FMM following the detection of trophoblast cells in the lungs of deceased
women. Bi-directional cell trafficking between mother and fetus is also altered in
pre-eclampsia and has been suggested to contribute to the underlying etiology. FMM
has been implicated in tolerance promotion, remission of auto-inflammatory disorders
during pregnancy, or the development of autoimmune conditions post-partum. The
underlying mechanism whereby the host immune system is modulated is unclear but
appears to involve HLA class II molecules, in that incompatibility between mother
and fetus promotes remission of rheumatoid arthritis, whereas feto-maternal HLA
compatibility may assist in the post-partum initiation of scleroderma. Couples having
a high degree of HLA class II compatibility have an increased risk for pre-eclampsia,
while the occurrence of scleroderma and rheumatoid arthritis is greater in pre-eclamptic
cases than in women with normal pregnancies, suggesting a long term autoimmune
predisposition. Since pregnant women with pre-eclampsia exhibit significantly lower
levels of maternally-derived micro-chimerism, the question arises whether pre-eclampsia
and post-partum development of autoimmune conditions occur due to the failure of the
grandmothers cells to adequately regulate an inappropriate micro-chimeric constellation.
Keywords: feto-maternal microchimerism, pre-eclampsia, non-inherited-maternal-antigens, cell-free DNA,
autoimmunity
FMM AND PRE-ECLAMPSIA: HISTORICAL OBSERVATIONS
Granted that pre-eclampsia, a severe life-threatening disorder of pregnancy characterized by
hypertension, proteinuria and organ failure is proposed to arise from dysfunctional placentation
(1). It is hardly surprising that many key observations concerning feto-maternal cell trafficking and
ensuing micro-chimerism were made in this context (2, 3).
In this regard, it is generally accepted that the first evidence of FMM was made at the turn of
the nineteenth century by Georg Schmorl; a German pathologist in his examination of pregnant
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women who had succumbed to eclampsia (2, 4). Eclampsia is the
fulminant form of pre-eclampsia where very severe symptoms are
accompanied by seizures (1). In his report, Schmorl documented
the occurrence of multi-nucleate trophoblast cells in the lungs
of 14 out 17 cases with eclampsia. It is noteworthy that this
feature was absent in 4 pregnant women who had died from
other causes, suggestive that it may be linked to the underlying
pathology of eclampsia (2, 4). Due to the potential role of
the placenta as a key aetiological trigger in pre-eclampsia, the
pivotal findings of Schmorl relating FMM to altered placentation
proved to be worthy of more than passing interest and formed
the basis of numerous other studies examining trophoblast
deportation, the release of trophoblast micro-particles or even
cell-free DNA from the placenta in cases with eclampsia
or pre-eclampsia (5–7). Consequently, it was worthwhile
reappraising Schmorl’s widely-cited seminal report in translated
form (4).
These were, however, not the only early reports suggesting
that pre-eclampsia may be associated with altered feto-maternal
cell trafficking. In 1905 Diehl postulated that pre-eclampsia
may result from increased transfusion of incompatible fetal
blood cells into the maternal compartment (2). This hypothesis
fitted with the then current concept of pre-eclampsia being
a form of pregnancy toxemia, triggered by toxins, possibly
of placental origin during pregnancy (8). Further evidence
supporting enhanced feto-maternal bleeding in pre-eclampsia
was provided by epidemiological observations suggesting that
the frequency of immunization due to Rhesus D incompatibility
was greater in pregnancies affected by pre-eclampsia than in
those with healthy deliveries (9). Since the Rhesus D antigen
is expressed exclusively on cells of the erythrocyte lineage (10),
such maternal immunization could not be due to the increased
presence of placental trophoblast but would of necessity involve
the increased presence of fetal red blood cells in the maternal
circulation. This vital aspect was subsequently confirmed by the
use of the then novel Kleihauer-Betke stain, which permitted
the detection of fetal erythrocytes in maternal blood samples
(11). This indicated that their proportion was indeed greater
in pregnancies affected by pre-eclampsia (12). These data
thereby provided further insight into the placental lesion in pre-
eclampsia, indicating that it involved both increased trophoblast
shedding, as well as leakage of fetal blood cells across the villous
barrier (2, 3).
FMM: THE QUESTION OF FETAL
CELLS PERSISTENCE
Possibly one of the most exciting subsequent developments
was the detection of fetal leucocytes in mitogen stimulated
maternal blood samples, wherein male fetal cells could be
detected by the presence of a Y chromosome (13). While this
finding was confirmed in a number of ensuing studies, these
did highlight the possible longevity of such fetal leucocytes as
they could be detected for a considerable period post-partum
(14–16). Indeed, the question arose whether such persisting
fetal cells could contribute to the presence of male leucocytes
in maternal blood samples from pregnancies with a female
fetus (14–16).
In a landmark finding the research group of Diana Bianchi
reported on the detection of circulatory fetal cells with stem cell-
like characteristics for a period of almost three decades post-
delivery (17). Subsequent studies have revealed that fetal cell
persistence is a frequent event occurring both in mouse and man,
and that this affects a variety of tissues including the brain (18–
20). As we shall observe in the continuation of this discourse,
the longevity of trafficking fetal cells provided the impetus for
a number of other investigative routes, particularly with regard
to the development of autoimmune conditions since women are
more prone to develop them post-partum (21).
FMM: THE QUEST FOR NON-INVASIVE
PRENATAL DIAGNOSIS LEADS TO
NEW DEVELOPMENTS
The advent of amniocentesis and karyotyping revolutionized
obstetrical practice by facilitating the prenatal assessment of
fetal chromosomal anomalies, such as trisomy 21 occurring
in Down syndrome (22). A caveat of such invasive prenatal
diagnostic procedures, especially that of chorionic villous
sampling performed earlier in gestation, was the risk of
injury to mother and potential loss of the unborn fetus (23–
25). Consequently, the need was voiced for safe efficacious
alternatives, thereby fuelling the quest for methods permitting
non-invasive prenatal diagnosis. It was therefore a foregone
conclusion that the prior reports of FMM would provide
the basis for the development of such novel prenatal tests
(26). Thus, most of these early studies focussed either
on the detection of fetal cells in maternal blood while
a few examined for the presence of trophoblast cells in
the cervix of pregnant women (27). Due to their scarcity,
fetal cells in maternal blood had to be enriched with most
centers using either flow cytometric or magnetic cell sorting
approaches (28).
The fetal erythroblast, also termed nucleated red blood
cell, emerged as the target cell of choice for fetal cells in
maternal blood-based strategies. This was largely due to its
abundance in the fetal circulation, its short half-life that
precluded any issue pertaining to longevity, as well as the
availability of suitable markers for enrichment (CD71) and
identification (fetal and embryonic hemoglobin) (26, 28). By
the use of multi-color FISH (fluorescent in-situ hybridization)
early studies suggested that it may be possible to detect the
most common fetal aneuploidies by this approach (28, 29),
while the use of single cell PCR permitted the detection of
Mendelian disorders i.e., hemoglobinopathies (30, 31). These
encouraging results promoted the assessment of this challenging
route in two independent NIH and EU funded studies (32,
33). Unfortunately, both of these multicenter studies revealed
that the paucity of fetal erythroblasts in maternal circulation
rendered their use impractical in daily clinical routine since
the required level of specificity and sensitivity could not be
attained (32, 33).
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During these explorations our group did make two
pertinent observations with regard to feto-maternal cell
trafficking in preeclampsia. In the first study, by the use of
male singleton pregnancies and multi-color FISH for the X
and Y chromosomes we could irrevocably demonstrate a
significantly increased presence of male fetal erythroblasts in
the maternal circulation in cases that manifest pre-eclampsia
when compared to matching healthy control pregnancies
(34). Furthermore, in an examination of maternal blood
samples collected from an at-risk cohort we observed an
increase in male fetal erythroblasts in samples from cases
that subsequently developed pre-eclampsia (35). Therefore,
these results confirmed that the underlying placental lesion in
pre-eclampsia facilitated leakage across the usually tight feto-
maternal barrier and that this defect was an early event in the
course of this disorder occurring prior to clinical manifestation of
symptoms (2, 3).
FMM: NOT RESTRICTED TO CELLS BUT
ALSO INCLUDES CELL-FREE DNA
During the “NIHNIFTY” study that explored the use of fetal cells
for non-invasive prenatal diagnosis the discovery of fetal cell-
free DNA (cfDNA) in maternal plasma or serum was reported
by Dennis Lo and colleagues in Oxford using Y chromosome
specific PCR (36). The basis for the Oxford study were reports
on the presence of tumor-derived cfDNA in cancer patient sera
(37, 38). In an extension of their original findings they observed
that maternally-derived cfDNA fragments could be detected in
cord blood samples indicating that FMM was not restricted to
the cross placental traffic of cells but could also involve cellular
cfDNA fragments (39).
The use of real-time PCR permitted a rapid and precise
assessment of the concentration of cfDNA in maternal blood
samples. This indicated a progressive increase during pregnancy,
peaking at term and ending with rapid clearance post-partum
(40). Due to our interest in pre-eclampsia we performed
several detailed investigations using qRT-PCR assays. These
indicated that manifestation of pre-eclampsia was associated
with a significant increase in the concentration of both fetal
and maternally-derived cfDNA, which correlated with disease
severity and being greatest in cases complicated with HELLP
(hemolysis, elevated liver, low platelet) syndrome or eclampsia
(41). Furthermore, we observed that when the blood samples
were drawn early during pregnancy prior to the onset of clinical
symptoms only the level of fetal cfDNA but not maternal cfDNA
was elevated (42, 43). Since fetal cfDNA was determined to
arise from the placenta this provided further evidence that
the underlying etiology of pre-eclampsia involved placental
lesions that occurred early in the cascade of events leading
to clinical manifestation (3). It is still unclear whether or
not elevations in the amount of fetal cfDNA contribute to
the development of pre-eclampsia or other pregnancy-related
disorders, such as preterm labor (44). The reason for this was
that by its hyper-methylated status, fetal cfDNA could trigger
an inflammatory response via TLR (toll like receptor) activation,
thereby playing a crucial initiatory role (44). Unfortunately
no clear data exists to support this enticing hypothesis (45).
The question as to the source of elevated maternal cfDNA
molecules was more complex to answer and took a rather
unexpected turn when it was finally revealed to be derived from
excessive generation of neutrophil extracellular traps (NETS) in
pre-eclampsia (46, 47).
The advantage of cfDNA over fetal cells in maternal blood
for prenatal diagnostic approaches quickly became apparent,
particularly when examining for fetal genetic loci absent
from the maternal genome, such as the Y chromosome for
male fetuses, or the Rhesus D gene in Rhesus D pregnant
women (48). Furthermore, the exploitation of the post-
genomic advent of massive parallel sequencing permitted the
reliable detection of fetal chromosomal abnormalities, such as
trisomies, thereby ushering this long sought goal into clinical
practice (48, 49).
FMM: RHEUMATOID
ARTHRITIS—AMELIORATION,
PREVENTION OR PROMOTION?
Amongst the autoimmune rheumatic disorders, rheumatoid
arthritis probably responds most favorably to pregnancy in that
many cases exhibit amelioration or remission whilst women
affected by systemic lupus erythematosus frequently have poor
pregnancy outcome characterized by high rates of pre-eclampsia
or even fetal loss (50, 51).
Since the beneficial effect of pregnancy on rheumatoid
arthritis disease status was determined not to be due to the action
of immune-suppressive hormones, Lee Nelson and colleagues
examined whether an HLA-based interaction between mother
and fetus could contribute to disease improvement (52, 53).
For their study they focussed on HLA Class II antigens due
to the predisposing effect of certain alleles on rheumatoid
arthritis incidence. In their analysis of 57 pregnancies from
41 women with rheumatoid arthritis remission was noted in
22 and amelioration in 12 instances. In 12 pregnancies no
improvement of rheumatoid arthritis symptoms were noted
(52). Their data indicated that a disparity in MHC class II
alleles existed between mother and fetus in those pregnancies
exhibiting a remission or improvement of rheumatoid arthritis
symptoms. These were most pronounced for HLA-DRB1, DQA
and DQB. Limited allelic differences were noted in the 12
rheumatoid arthritis cases where no improvement of symptoms
was offered by pregnancy. This association between MHC class
II disparity and disease activity was also evident in instances
in women having successive pregnancies where rheumatoid
arthritis symptoms were reduced in one instance but not the
other. At the time that these studies were conducted, no
conclusions could be drawn as to the operative mechanism
although the question of trafficking fetal cells and FMM were
raised (52).
Pregnancy may, however, not only afford some temporary
respite from rheumatoid arthritis but may prevent or reduce
the onset of this debilitating disorder post-partum (54). In
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order to examine whether pregnancy provided a protective
effect against the development of rheumatoid arthritis, Guthrie
and colleagues examined 310 women with newly diagnosed
rheumatoid arthritis in comparison to 1,418 control women
(54). This study indicated that the occurrence of rheumatoid
arthritis was indeed lower in women who had been pregnant
and delivered healthy babies by a factor of almost 40% when
compared to non-parous women. It was furthermore observed
that no reduction in the risk of developing rheumatoid arthritis
was evident in women who had been pregnant but had not
continued with the pregnancy until delivery (54). There was
also no evidence for a cumulative protective effect offered by
multiple deliveries. In contrast it appeared that the greatest
protective effect offered by pregnancy was in a period of 5
years or less after delivery, and that this effect diminished
significantly by 15 years post-partum. The authors proposed that
the protective effect offered by a completed pregnancy may be
attributable to persisting fetal cells. This could account for the
diminished influence observed in pregnancies not completed
to term, as cross-placental cell trafficking would be limited in
these instances. The mechanism whereby micro-chimeric fetal
cells would favorably modulate the maternal immune system to
prevent rheumatoid arthritis onset may be by the provision of
disparate MHC class I alleles as described above. Furthermore,
in parous women deemed to be at high risk for rheumatoid
arthritis due to the presence of two copies of HLA alleles,
such as certain HLA-DRB1 loci, micro-chimeric fetal cells
may be able to offset disease development by the provisional
protective HLA molecules, such as the “DERAA” HLA-DRB1
locus. Evidence that such a mechanism may be operative is
provided by the report of Pietsma and colleagues who observed
that the protective “DERAA” locus in the form of a non-
maternally inherited allele (NIMA) lead to a diminished risk for
rheumatoid arthritis (55). The NIMA mechanism is discussed in
more detail below.
On the other hand, FMM could assist with the initiation of
an auto-inflammatory condition by provision of the necessary
genetic background (56). An example of this is the “shared
epitope” of certain HLA-DRB1 alleles associated with an
increased incidence of rheumatoid arthritis (57). This “shared
epitope” is a highly similar five amino acid peptide sequence
contained in the HLA-DRB1∗04 allele. In an elegant study
Yan and colleagues set out to address whether FMM could
contribute to the development of rheumatoid arthritis in women
who were genetically “shared epitope” negative (58). In this
study they examined 52 cases with rheumatoid arthritis and
34 healthy controls; 84% of cases and 92% of controls had
at least one live birth. The mean age of cases was 51 and
that of controls 42 years. By the use of “shared epitope”
specific PCR assays they assessed the degree of microchimerism
for such alleles in their study and control groups. Although
some degree of “shared epitope” specific signals could be
detected in both cohorts, the extent was significantly greater
in cases with rheumatoid arthritis (58). In addition, the level
of FMM for these “shared epitopes” was higher in rheumatoid
arthritis cases than controls. Therefore, FMM, can contribute
to the subsequent development of an autoimmune condition
i.e., rheumatoid arthritis by the provision of necessary HLA
haplotypes it via the inheritance of fetal cells or maternal cells
during pregnancy (58).
FMM: CELLS FROM GRANDMA ARE
MISSING IN PRE-ECLAMPSIA
During pregnancy, the pregnant woman exhibits a complex
micro-chimeric phenotype, hosting cells from her current fetus,
cells from previous pregnancies as well as cells from her mother
(56, 59). Following the discovery of persisting fetal cells and
their possible role in autoimmune conditions like systemic
sclerosis, Maloney and colleagues investigated the behavior of
trafficking maternal cells. Their examination, which employed
HLA specific PCR assays as well as the use of XY FISH to detect
female cells in male offspring revealed that cells of maternal
origin can persist for numerous decades well into adulthood
(59). In most instances maternal cells were HLA class I and
II disparate from those of the host offspring (59). To study
whether trafficking maternal cells play a role during pregnancy,
Gammil et al. examinedmaternal blood samples collected in each
trimester of pregnancy and post-partum (60). In some instances,
they also had access to samples drawn prior to conception. By
the use of quantitative PCR for specific HLA loci they were
able to assess the extent of microchimerism attributable to
trafficking maternal cells. In their examination of 86 maternal
blood samples obtained from 27 healthy pregnant women with
normal deliveries, no trafficking maternal cells were detected
pre-conception or in samples obtained in the first trimester of
pregnancy. On the other hand, such cells could be detected in
16% of second trimester, 29% of third trimester and 14% of
post-partum samples. The degree of trafficking maternal cells
microchimerism was greatest in samples collected close to term
(60) (Figure 1). A startling finding made during this study was
that no evidence of microchimerism due to trafficking maternal
cells could be detected in any of the samples obtained from
20 pregnant women with manifest pre-eclampsia, in contrast to
matching healthy control pregnant women, where such micro-
chimeric cells could be detected in 30% of cases (60). This result
could have profound implications since trafficking maternal
cells are potentially important immune modulators due to their
expression of NIMA (see below).
FMM: THE ROLE OF NIMA
A number of early reports indicated that cross-placental cell
traffic was not restricted to the fetus but could also be
derived from the mother. Pioneering works performed by
Owen and colleagues in 1954 observed that Rh-negative girls
born from Rh-positive mothers develop very low amount
of antibodies to Rh suggesting the existence of a tolerance
mechanism to NIMA (61). Later and in the setting of solid
organ transplantation tolerance, Claas et al. observed that 50%
of the patients receiving several blood transfusions showed
selective anergy to non-inherited HLA haplotypes (62). Similarly,
Burlingham and colleagues describe that graft survival between
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FIGURE 1 | Microchimerism throughout generations and risk of pre-eclampsia, RA and SSc development. Compatible or disparate expression of HLA of
non-inherited antigen present in subsequent generation seam to promote or ameliorate autoimmunity or favor pre-eclampsia.
siblings who are mismatched with the recipient for one HLA
haplotype results in higher graft survival when the donor
has maternal HLA antigens not inherited by the recipient
than when the donor has paternal antigens not inherited by
the recipient suggesting and highlighting an important role
for NIMA (63). More works performed in this direction
conclude that the risk of graft vs. host disease among NIMA-
matched stem cell transplants is reduced, suggesting possible
clinical benefits of NIMA-specific tolerance that persists in
individuals through to adulthood (64, 65). Post-natal persistence
of genetically foreign chimeric maternal cells in offspring was
originally described in infants with severe combined immune
deficiency. In a study of 121 infants with defective T and
B lymphocyte development, 40% had engrafted maternal T
cells and a similar proportion developed clinically apparent
graft-vs.-host disease caused by anti-fetal-allo-immunity (66,
67). Mother to offspring transfer and persistence of maternal
cells is likely an unavoidable by-product of a porous placental
interface. In this scenario, post-natal persistence of NIMA-
specific tolerance represents an expendable developmental
remnant of immune suppressive mechanisms essential for in
utero survival (68). Very interesting is the role of NIMA during
fetal life: Kinder and colleagues showed that the developmental
exposure to foreign maternal cells primes the expansion and
accumulation of NIMA-specific immune suppressive regulatory
T cells that help establishing better tolerance (68, 69). The
persistence of those regulatory T cells could then reinforce
fetal tolerance during the next generation pregnancies sired by
males with overlapping MHC haplotype specificity, conferring a
reproductive advantage.
Taken together, genetic fitness is not restricted to chromosome
transmission but is expanded through vertical transfer and
survival of tolerogenic cells that establish microchimerism in
offspring favoring in return the preservation of NIMA. On
the other hand, cross-generational reproductive advantages that
preserve post-natal retention of microchimeric maternal cells
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may also perpetuate auto-inflammatory or autoimmune diseases
in offspring (56).
FMM: SYSTEMIC
SCLEROSIS—TRIGGERED BY
PERSISTING FETAL CELLS?
Unlike rheumatoid arthritis where the risk is diminished
post-partum, systemic sclerosis, an autoimmune disorder
characterized by graft-vs.-host disease like symptoms has a
strong predilection in women post-partum (21). It was therefore
hypothesized that persisting fetal cells may play a role in initiation
of systemic sclerosis (21). In order to address this possibility, a
group of 40 women who had previously given birth to a son
were recruited. Of these, 17 were affected by systemic sclerosis,
7 were sisters of affected cases and 16 were healthy matching
controls. The degree of fetal cell persistence in the circulation
was assessed by a quantitative PCR assay specific for the Y
chromosome. This analysis indicated that the median level of
male positive cells was significantly higher in the circulation
of systemic sclerosis cases than in matching controls, with
intermediate levels being recorded in the 7 siblings (21). Since
rheumatoid arthritis remission or amelioration during pregnancy
involves a disparity in HLA class II, the role of such an interaction
between mother and fetus was examined also in the systemic
sclerosis cases. This indicated that a high degree of compatibility
between mother and child existed for HLA DRB11, DRB12,
DQA1, and DQB1 in systemic sclerosis cases (21). Since this
feature was not evident in the healthy controls group, it is possible
that microchimerism due to persisting HLA compatible fetal
cells may contribute to the development of systemic sclerosis
post-partum (Figure 1).
FMM: WHAT IS THE INFLUENCE OF
PRE-ECLAMPSIA ON INCIDENCE OF
SYSTEMIC SCLEROSIS OR
RHEUMATOID ARTHRITIS?
As our report on elevated trafficking of fetal cells in pre-eclampsia
(34) was published at around the same time as that of persisting
fetal cells in systemic sclerosis (21), we queried whether the
incidence of systemic sclerosis was higher in women who had
pre-eclamptic pregnancies (26). Unfortunately, we did not have
the correct epidemiological data set at our disposal at the time
and so this hypothesis lay resting for almost two decades to finally
be addressed in two recent reports (70, 71). In the first van Wyk
and colleagues examined whether a relationship existed between
the incidence of pre-eclampsia and subsequent development of
systemic sclerosis (70). In their study cohort (n = 103), the
incidence of systemic sclerosis post-first delivery was in mean
after 27 years. The authors also determined that systemic sclerosis
occurred with greater frequency in women who had pregnancies
affected by pre-eclampsia or fetal growth restriction. A limitation
of this study was that no information was available concerning
potential HLA compatibility, a facet which would have been
most interesting to investigate; on one hand in view of previous
findings reporting on FMM (21), on the other hand due to
reports indicating that pre-eclampsia may occur with greater
frequency in instances where a high degree ofMHC compatibility
for the HLA-DR, -DP, and -DQ alleles occurs between spouses
(72). In the second study, which made use of the Danish
national register from which the pregnancy outcome and co-
incidence of systemic sclerosis for 778,758 women was obtained
(71). This indicated that the occurrence of pre-eclampsia is
associated with a 69% risk of developing systemic sclerosis. Once
again, unfortunately no details concerning HLA types could
be obtained.
In the instance of post-partum development of rheumatoid
arthritis, the issue is somewhat more complex with a major
difference existing with regard as whether the pregnancy was
healthy or disturbed by pre-eclampsia. As discussed above,
it is widely accepted that prior pregnancy has a beneficial
effect on reducing the subsequent development of rheumatoid
arthritis. Indeed, it has even been suggested that parity may
serve as a vaccine to prevent post-partum rheumatoid arthritis,
especially in the first 5 years after the last delivery (54). This
is in stark contrast to what is observed if the pregnancy was
affected by pre-eclampsia, where an alternate scenario emerges
in that such a constellation may favor post-partum rheumatoid
arthritis. Evidence of such a feature was initially obtained by
epidemiological data mining of the Danish National Patient
Register where a retrospective examination suggested that pre-
eclampsia was associated with an increased risk for post-partum
development of rheumatoid arthritis (73). This feature was
confirmed in a subsequent more detailed examination of 55,752
pregnant women of which 169 developed rheumatoid arthritis
during the follow up period (74). The incidence of pre-eclampsia
was greater in the rheumatoid arthritis study group (6.5%) than
in the control cohort (3.6%) suggesting that pre-eclampsia lead
to an increased risk for rheumatoid athritis (R.H = 1.96). On
the basis of these findings the authors argued that rheumatoid
arthritis may be associated with a long pre-clinical phase prior to
symptom manifestation, a feature which may affect pregnancy
outcome and thereby promote pre-eclampsia, or that a shared
predisposition for pre-eclampsia and rheumatoid arthritis may
exist (74) (Figure 1). In an independent study Ma and colleagues
examined whether adverse pregnancy outcome as measured by
extreme (≤1,000 g) or very low birth weight (≤1,500), a common
feature of severe pre-eclampsia, was associated with subsequent
clinical manifestation of rheumatoid arthritis (75). In their study
they examined 202 cases with rheumatoid arthritis and 1,102
controls. This analysis indicated that both extreme and very
low birth weight had a 3- to 5-fold greater risk of rheumatoid
arthritis, particularly for the rheumatoid factor positive
form (75).
FMM: THE PRE-ECLAMPSIA
CONUNDRUM AND THE ROLE OF NIMA
The incidence of pre-eclampsia, particularly the severe form
involving a defect in placenta development and spiral artery
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modification is associated with a high degree of HLA class II
compatibility between spouses specifically for the HLA-DR, -
DP, and -DQ alleles (72). Since trans-placental fetal cell traffic is
enhanced in cases with pre-eclampsia (34), this would lead to a
high level of microchimerism involving HLA class II compatible
fetal cells of the type previously observed in cases with systemic
sclerosis, autoimmune condition characterized by graft-vs.-host
disease-like lesions (21). In this context it is worth noting
that previous studies have suggested that pre-eclampsia exhibits
traits of an autoimmune condition with placental features akin
to graft-vs.-host disease (76). The question, hence, arises if a
histo-compatible FMM state contributes to the etiology of pre-
eclampsia. It is also plausible that the presence of this high
grade pro-autoimmune microchimeric setting in pre-eclampsia,
involving a greater than normal dosage of fetal cells, contributes
to the subsequent increased risk for systemic sclerosis and
rheumatoid arthritis occurring years later in an extended post-
partum period (71, 74).
As pointed out above, microchimerism in a pregnant
woman not only involves cells from the current fetus, but
also that of any previous pregnancies as well as trafficking
maternal cells the proband inherited from her mother (60).
Due to their expression of NIMA, these trafficking maternal
cells are important in inducing tolerance. A striking feature
of pre-eclampsia is the apparent lack of trafficking maternal
cells (60). It is therefore possible that the immunological
effect of the microchimeric imbalance occurring in pre-
eclampsia due to an influx of fetal cells may be further
skewed by the apparent lack of trafficking maternal cells in
the proband. Consequently, there is no mechanism in place
to check or dampen the deleterious action of FMM derived
haplo-identical or similar HLA alleles. Since pregnancy is
an inflammatory process characterized by basal activation
of circulatory neutrophils (77), this could in combination
with a micro-chimeric aberrancy provide the necessary
stimulus for the dysregulation observed in pre-eclampsia.
In a similar manner, the combination of a lack or reduced
level of trafficking maternal cells and high grade fetal
microchimerism of disease associated HLA alleles could
contribute to post-partum onset of rheumatoid arthritis or
systemic sclerosis.
SUMMARY AND CONCLUSIONS
While feto-maternal exchange in pregnancy was previously
viewed as rare and innocuous event, a vast body of work in the
interim has shown that it is a common feature of mammalian
pregnancy being readily discernible from mouse to man. The
effects of this exchange are far reaching and can persist into
adulthood and possibly even old age. In this review we have
highlighted the potential anomaly regarding FMM occurring in
pre-eclampsia and how this could contribute to the etiology
of this enigmatic disorder, but also to the development of
autoimmune diseases years post-partum. Should an imbalance
between trafficking maternal cells and newly acquired fetal
microchimerism prove to be a pivotal trigger driving these
developments, then it is highly likely that an altering of the
microchimeric milieu could be used to modulate or steer the
maternal immune system away from this destructive direction.
Evidence that such a mechanism may be viable is provided by
reports indicating that the incidence of pre-eclampsia is reduced
in women who have received blood transfusions, an event known
to lead to a microchimeric state (78). It could therefore transpire
that we are on the cusp of new era in the field of microchimerism,
whereby this phenomenon provides the basis for new cell-based
therapies geared at immune modulation and if so, what better
target than pre-eclampsia.
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